Precision Biosensor: Q1 2026 Consolidated Operating Profit Turns Positive, Revenue Up 52%

Revenue of KRW 7.03bn (up 52% YoY), operating profit of KRW 0.17bn (turnaround), net profit of KRW 1.33bn (vs -KRW 2.02bn in Q1 2025)
Debt ratio improved to 46.7% (vs 62.0% at year-end 2025)
Completed absorption merger with CitiBio in Feb 2026 (issued 3.99mn new shares, recognized goodwill of KRW 8.09bn)
Largest shareholder Kwangdong Pharmaceutical holds 50.23% (post-merger)
Outstanding balance of 2nd and 3rd convertible bonds: KRW 6.5bn (conversion prices: KRW 3,540/3,396)
R&D expenses: KRW 0.59bn (8% of revenue)
Accumulated deficit: KRW 49.4bn; no dividends